Author

Leonardo Salese

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Leonardo Salese  et al.

PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME
PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME

Leonardo Salese  et al.

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME
PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

Leonardo Salese  et al.

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Leonardo Salese  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME

Leonardo Salese  et al.

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019

Leonardo Salese  et al.

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS
EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

Leonardo Salese  et al.

Item 1 - 7 / 7
1